NCT00502463 (ASOG-HNO1) is a NA clinical trial of Docetaxel in Head and Neck Cancer, sponsored by Austrian South Oncology Group.

Who is sponsoring NCT00502463?

NCT00502463 is sponsored by Austrian South Oncology Group.

What drugs are being tested in NCT00502463?

Interventions in NCT00502463: Docetaxel, Cisplatin, 5-FU, Radiotherapy, Cetuximab.

What condition does NCT00502463 study?

NCT00502463 studies Head and Neck Cancer.

Is NCT00502463 still recruiting?

NCT00502463 is currently completed. Last updated 7 February 2024.

Last reviewed 2024-02-07 · How we verify

NCT00502463: ASOG-HNO1

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Induction Chemotherapy Prior to Radio-immunotherapy in Head and Neck Cancer Stage III/IV - a Methodical Trial

Completed NA Last updated 7 February 2024

What this trial tests

NA trial testing Docetaxel in Head and Neck Cancer in 51 participants. Completed in 19 January 2014.

Timeline

3 October 2007

Primary endpoint
19 January 2010

19 January 2014

Quick facts

Lead sponsor	Austrian South Oncology Group
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	51
Start date	3 October 2007
Primary completion	19 January 2010
Estimated completion	19 January 2014
Sites	5 locations across Austria

Drugs / interventions tested

Docetaxel (Docetaxel) — full drug profile →
Cisplatin (cisplatin) — full drug profile →
5-FU
Radiotherapy
Cetuximab (cetuximab) — full drug profile →

Conditions studied

Head and Neck Cancer — all drugs for Head and Neck Cancer →

Sponsor

Austrian South Oncology Group

Who can join

Adults 18 to 75, any sex, with Head and Neck Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the trial is to determine the feasibility of an induction chemotherapy with radio-immunotherapy in patients with head and neck cancer stage III/IV

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Docetaxel

Trials testing the same drug.

NCT06724042 — Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors · Phase 1 · not yet recruiting
NCT07361484 — Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy a · Phase 3 · not yet recruiting
NCT07415031 — A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies · Phase 2 · not yet recruiting
NCT07528274 — Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure · Phase 2 · recruiting
NCT07487896 — A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esopha · Phase 3 · not yet recruiting

Other recruiting trials for Head and Neck Cancer

Currently open trials in the same condition.

NCT07318220 — Prehabilitation Protocol for Head and Neck Cancer Patients · NA · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07467083 — Development and Application of a Nurse-Led Preemptive Symptom Management Protocol for Head and Neck Cancer Patients Unde · Phase 3 · recruiting
NCT07209189 — Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-esca · Phase 2 · recruiting
NCT06837480 — Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00502463 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Austrian South Oncology Group
Last refreshed: 7 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00502463.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing